BRIEF-AstraZeneca Says Farxiga Granted U.S. Priority Review For CKD

Reuters | Updated: 06-01-2021 12:58 IST | Created: 06-01-2021 12:47 IST
BRIEF-AstraZeneca Says Farxiga Granted U.S. Priority Review For CKD
AstraZeneca logo Image Credit: ANI

AstraZeneca PLC:

ASTRAZENECA PLC - FARXIGA GRANTED US PRIORITY REVIEW FOR CKD

ASTRAZENECA - FARXIGA COULD BECOME FIRST SGLT2 INHIBITOR APPROVED TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE, WITH AND WITHOUT TYPE-2 DIABETES Source text for Eikon: Further company coverage:

TRENDING

1
US forces exit Iraq, emboldening Iran's proxies and Islamic State

US forces exit Iraq, emboldening Iran's proxies and Islamic State

Global
2
North Korea says South Korea to pay a price for shifting blame for mine blast

North Korea says South Korea to pay a price for shifting blame for mine blas...

Global
3
US Senate blocks measure demanding report on rights violations in West Bank

US Senate blocks measure demanding report on rights violations in West Bank

Global
4
China vows response if EU introduces moves targeting Chinese trade

China vows response if EU introduces moves targeting Chinese trade

Global

PERSPECTIVES AND INSIGHTS

Finance, Technology and Better Jobs: The Forces Reshaping Human Development in West Africa

The Tariff Trap: How Protectionism Could Cost the US While Reshaping World Trade

The Global Road Safety Gap Is Growing Even as Death Rates Fall

Resource-Rich, Ecologically Trapped? Digital Transformation May Be the Escape Route

DevShots

Latest News

Connect us on

LinkedIn Quora Youtube RSS
Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.

Subscribe to our Newsletter  

STANDARDS & POLICIES

EDITIONS

OTHER LINKS

CONNECT

Devdiscourse
Disclaimer | Terms of use | Privacy Policy

© Copyright 2026